The Centers for Medicare and Medicare Services’ upcoming national coverage determination for amyloid-directed monoclonal antibody drugs for Alzheimer’s disease should be flexible enough to provide “appropriate” coverage for different therapies in the class based on individual labeling, Eli Lilly and Company and Genentech, Inc. urge in separate comments submitted to CMS 11 August.
A “class-based coverage determination may be premature,” Lilly said, adding: “We urge CMS to ensure that its coverage decision...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?